Biotech Stocks

Sesen Bio (SESN) Draws Price Target Lift from H.C. Wainwright Following Strong Initial Pivotal Trial Results

H.C. Wainwright’s Swayampakula Ramakanth now bets on 54% in return potential for SESN stock on the heels of encouraging 3-month data in NMIBC.

RBC Capital Makes a Bullish Case for Celgene (CELG) Amid Overblown Share Weakness

RBC Capital’s Brian Abrahams believes that the exit of Celgene’s former BD chief is causing an unwarranted dip in the stock; here’s why.

Could Transenterix (TRXC) Boost Its Total Addressable Market Double by the End of 2018? RBC Capital Shares Key Insights

RBC Capital’s Glen Novarro walks away upbeat on TRXC’s market opportunity following an encouraging non-deal roadshow with CFO Joe Slattery.

Eiger (EIGR) Successfully Licensed Rights to Progeria; Wedbush Boosts Price Target

Many investors hope to win big on biotech stocks as shares can skyrocket when there’s …

Oppenheimer Comments on Celgene (CELG) After ASCO Abstracts Reveal

The annual meeting of the American Society of Clinical Oncology (commonly known as ASCO) is …

Novavax (NVAX) Stock: The Trip to Canaccord’s $10 Mark

B.Riley FBR analyst George Zavoico is out today with a bullish note on shares of Novavax (NASDAQ:NVAX), …

Maxim Comments on Interpace Diagnostics (IDXG) Following 1Q18 Update

Maxim analyst Jason McCarthy is out today with a research note on shares of Interpace Diagnostics (NASDAQ:IDXG), …

H.C. Wainwright Looks Beyond Palatin Technologies (PTN) FQ3 Outcome to FDA’s Big Decision on Bremelanotide

H.C. Wainwright’s Joseph Pantginis sees a “compelling” buying opportunity in PTN shares for biotech investors.

Synergy Pharmaceuticals (SGYP): Can Trulance Uptake Grow Stronger? Oppenheimer and Cantor Weigh in

Oppenheimer’s Christopher Liu and Cantor’s William Tanner see potential in Synergy’s Trulance, even if its momentum is not full steam ahead just yet.

Synergy Pharmaceuticals (SGYP) GI Asset Trulance Volumes Just Keep Getting Better; BTIG Weighs In

BTIG’s Tim Chiang is out with a positive research note, singing the praises of SGYP and 1Q earnings that put Trulance’s potential in the limelight.